XOMA XOMA Corporation
Partial data40.17USD0.00%Mkt Cap: 710.16M $P/E: 25.5982d ago
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty paymen…
Industry Peers
Biotechnology$129.20BUSDP/E 29.7
$89.83BUSD
$76.86BUSDP/E 18.5
$51.88BUSDP/E 31.4
$49.79BUSDP/E 32.4
$42.17BUSDP/E 18.0
$40.67BUSD
$40.33BUSDP/E 63.4
$32.90BUSDP/E 30.3
$31.13BUSDP/E 39.2
$25.60BUSD
$24.36BUSD
$22.86BUSDP/E 14.4
$22.79BUSDP/E 29.2
$21.90BUSDP/E 30.2
$21.97BUSD
$15.08BUSDP/E 17.6
$14.83BUSDP/E 18.9
$14.18BUSDP/E 15.0
$14.03BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Ligand Pharmaceuticals (LGND) Stock Looks Undervalued On Cash Flow Yet Overvalued On Earnings Ligand Pharmaceuticals stock has delivered a very large 338.7% return over the past three years, yet its valuation signals are split, with an intrinsic value estimate from a Discounted Cash Flow (DCF) model suggesting the shares trade below that estimate while market multiples and a low overall value score point to a richer pricing. The 338.7% three year return puts a spotlight on whether the current price already embeds much of the good news in Ligand Pharmaceuticals. The completed US$739m... | ||